Loading clinical trials...
Loading clinical trials...
A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge
Conditions
Interventions
larazotide acetate
placebo
+1 more
Locations
23
United States
Study Site
Scottsdale, Arizona, United States
Study Site
Colorado Springs, Colorado, United States
Study Site
Chicago, Illinois, United States
Study Site
Lexington, Kentucky, United States
Study Site
Hagerstown, Maryland, United States
Study Site
Boston, Massachusetts, United States
Start Date
August 1, 2007
Primary Completion Date
October 1, 2008
Completion Date
March 1, 2009
Last Updated
September 20, 2017
NCT07239336
NCT07039773
NCT06356220
NCT07069127
NCT04806620
NCT07177287
Lead Sponsor
9 Meters Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions